Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Delveinsight

AUGUST 6, 2020

The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

NOVEMBER 30, 2023

The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

JULY 26, 2022

At a basic level, the virus’s protein ‘coat’ and the enzymes it uses to gain control of the host cell’s DNA mutate frequently, making it difficult to target with therapeutics. The reason there has been, as yet, no effective cure for the condition is due to the complexity of the virus and the way in which it is activated within the body.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. In older adults, the same vaccine elicited neutralizing antibodies 1.6

Vaccination 92

Vaccination Vaccine Antibody Life Science 92